ArticleOncotarget2016
Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases.Virchows Archiv : an international journal of pathology · 2024Article
- Primary clear cell adenocarcinoma of the lung: a national analysis.Journal of thoracic disease · 2023Article
- Article
- Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy.Frontiers in oncology · 2022Article
- Article
- Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer.Annals of translational medicine · 2021Article
- Comprehensive Analysis of the Prognostic Role and Mutational Characteristics of m6A-Related Genes in Lung Squamous Cell Carcinoma.Frontiers in cell and developmental biology · 2021Article
- circSLC8A1 Acts as a Tumor Suppressor in Prostate Cancer via Sponging miR-21.BioMed research international · 2021Article
- Hippo Pathway Core Genes Based Prognostic Signature and Immune Infiltration Patterns in Lung Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Identification of Molecular Characteristics and New Prognostic Targets for Thymoma by Multiomics Analysis.BioMed research international · 2021Article
- Long Non-coding RNA FIRRE Acts as a miR-520a-3p Sponge to Promote Gallbladder Cancer Progression via Mediating YOD1 Expression.Frontiers in genetics · 2021Article
- Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.BioMed research international · 2021Article
- Integrative Analysis of Differently Expressed Genes Reveals a 17-Gene Prognosis Signature for Endometrial Carcinoma.BioMed research international · 2021Article
- RNA mInnovation (Cambridge (Mass.)) · 2020Review
- CircEIF4G2 Promotes Tumorigenesis and Progression of Osteosarcoma by Sponging miR-218.BioMed research international · 2020Article
- CircDENND2A Promotes Non-small Cell Lung Cancer Progression via Regulating MiR-34a/CCNE1 Signaling.Frontiers in genetics · 2020Article
- Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma.Computational and mathematical methods in medicine · 2020Article
- Clear cell adenocarcinoma of the lung: a SEER analysis.Translational lung cancer research · 2019Article
- Clinical Presentation and Treatment Options for Clear Cell Lung Cancer: University of Cincinnati A Case Series and Literature Review of Clear Cell Lung CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Comprehensive study of prognostic risk factors of patients underwent pneumonectomy.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung adenocarcinoma with clear cell component is extremely rare and the cases reported in literature remain scarce. The biological behaviors, clinicopathologic characteristics, mutational status and prognosis of lung adenocarcinoma with clear cell component are still uncertain.
methodsThirty-eight lung adenocarcinomas with clear cell component and 1659 lung adenocarcinomas were subjected to the study. All the corresponding clinicopathologic data, the distributions of relapse-free survival (RFS) and overall survival (OS), and the status of gene mutations were investigated.
resultsOf 1697 adenocarcinomas, 38 (2.2%) had clear cell component. Fifty percent of adenocarcinomas with clear cell component (11/22) harbored EGFR mutation, 41 percent (9/22) harbored KRAS mutation and 5 percent (1/22) harbored AKT1 mutation. Univariable analysis revealed that sex, age, tumor stage, tumor size, nodal stage and pathology were all significant predictors of RFS and OS while the tumor size and nodal stage were still significant predictors in multivariable analysis. There were significantly differences in RFS and OS for lung adenocarcinomas with clear cell component compared with those lung adenocarcinomas.
conclusionsLung adenocarcinoma with clear cell component is a rare, malignant tumor with poor prognosis and displays more frequent EGFR and KRAS mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.